ArticleBiometrics2010
Risk-group-specific dose finding based on an average toxicity score.
Article in Biometrics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.Stats · 2020Article
- Sequential designs for individualized dosing in phase I cancer clinical trials.Contemporary clinical trials · 2017Article
- Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.Statistics in medicine · 2015Article
- Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.Contemporary clinical trials · 2014Article
- Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.The open medical informatics journal · 2013Article
- Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.Contemporary clinical trials · 2012Article
- Continual reassessment method with multiple toxicity constraints.Biostatistics (Oxford, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We propose a Bayesian dose-finding design that accounts for two important factors, the severity of toxicity and heterogeneity in patients' susceptibility to toxicity. We consider toxicity outcomes with various levels of severity and define appropriate scores for these severity levels. We then use a multinomial-likelihood function and a Dirichlet prior to model the probabilities of these toxicity scores at each dose, and characterize the overall toxicity using an average toxicity score (ATS) parameter. To address the issue of heterogeneity in patients' susceptibility to toxicity, we categorize patients into different risk groups based on their susceptibility. A Bayesian isotonic transformation is applied to induce an order-restricted posterior inference on the ATS. We demonstrate the performance of the proposed dose-finding design using simulations based on a clinical trial in multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.